Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: Preliminary results of radiation therapy oncology group 0424

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 3, 2015, Pages 497-504

  Fisher, Barbara J ^a   Hu, Chen ^b   Macdonald, David R ^a   Lesser, Glenn J ^c   Coons, Stephen W ^d   Brachman, David G ^e   Ryu, Samuel ^f   Werner Wasik, Maria ^g   Bahary, Jean Paul ^h   Liu, Junfeng ⁱ   Chakravarti, Arnab ^j   Mehta, Minesh ^k  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e Arizona Oncology Services   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ GCE Solutions Inc   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLOGY; RADIOTHERAPY;

CHEMORADIATION THERAPIES; CONFIDENCE INTERVAL; LOW-GRADE GLIOMAS; METHODS AND MATERIALS; OVERALL SURVIVAL RATES; PROGRESSION FREE SURVIVAL; RADIATION THERAPY ONCOLOGY GROUPS; SIGNIFICANCE LEVELS;

TUMORS;

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; AGE DISTRIBUTION; AGED; ALLERGIC REACTION; ASTROCYTOMA; BLEEDING; BRAIN ISCHEMIA; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HERPES SIMPLEX ENCEPHALITIS; HIGH RISK PATIENT; HUMAN; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREAS DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SKIN DISEASE; SOFT TISSUE DISEASE; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR VOLUME; VASCULAR DISEASE; VISUAL DISORDER; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; GLIOMA; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, CONFORMAL; RESEARCH DESIGN; RISK FACTORS; YOUNG ADULT;

EID: 84923247998     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.11.012     Document Type: Conference Paper

References (42)

1. E. Shaw, M. Wang, and S. Coons Randomized trial of radiation therapy plus procarbazine, lomustine and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802 J Clin Oncol 30 2012 3065 3070
2. J. Quinn, D. Reardon, and A. Friedman Phase II trial of temozolomide in patients with progressive or recurrent low-grade glioma J Clin Oncol 21 2003 646 651
3. M. van den Bent, O. Chinot, and W. Boogerd EORTC Study 26972: Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, CCNU, vincristine) chemotherapy: EORTC phase II study 26 Ann Oncol 14 2003 599 602
4. S. Kesari, D. Schiff, and J. Drappatz Phase II study of protracted daily temozolomide for low-grade gliomas in adults Clin Cancer Res 15 2009 330 337
5. G. Kaloshi, A. Benouaich-Amiel, and F. Diakite Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome Neurol 68 2007 1831 1836
6. E. Galanis, J. Buckner, and P. Burch Phase II trial of nitrogen mustard, vincristine and procarbazine (MOP) in patients with recurrent glioma: North Central Cancer Treatment Group results J Clin Oncol 16 1998 2953 2958
7. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 56 2006 106 130
8. W. Mason, G. Krol, and L. DeAngelis Low grade oligodendroglioma responds to chemotherapy Neurology 46 1996 203 207
9. H.J. Eyre, J.J. Crowley, and J.J. Townsend A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group study J Neurosurg 78 1993 909 940
10. J. Quinn, D. Reardon, and A. Friedman Phase II trial of temozolomide in patients with progressive low-grade glioma J Clin Oncol 21 2003 646 651
11. R. Stupp, W. Mason, and M. Van Den Bent Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase 3 study. 5 year analysis of the EORTC-NCIC study Lancet Oncol 10 2009 459 466
12. F. Pignatti, M. van den Bent, and D. Curran Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 2002 2076 2084
13. A. Karim, B. Maat, and R. Hatlevoli A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844 Int J Radiat Oncol Biol Phys 36 1996 549 556
14. A. Karim, D. Afra, and P. Cornu Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BR04: An interim analysis Int J Radiat Oncol Biol Phys 52 2002 316 324
15. M. van den Bent, D. Afra, and O. de Witte Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomized trial Lancet 366 2005 985 990
16. J. Knisely, B. Lally, and D. Zelterman Validation of the European Organization for Research and Treatment of Cancer (EORTC) prognostic factors for low grade gliomas utilizing the Surveillance, Epidemiology and End Results (SEER) database Int J Radiat Oncol Biol Phys 63 2005 S262 S263
17. D.A. Schoenfeld, and J.R. Richter Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint Biometrics 38 1982 63 170
18. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
19. R. Peto, and J. Peto Asymptotically efficient rank invariant test procedures J Royal Stat 135 1972 185 207
20. D.R. Cox Regression models and life-tables J Royal Stat 34 1972 187 220
21. J. Cairncross, M. Wang, and E. Shaw Phase III trial of chemo-radiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402 J Clin Oncol 31 2013 331 343
22. Y. Ino, M. Zlatescu, and H. Sasaki Long-term survival and therapeutic responses in patients with histologically disparate high grade gliomas demonstrating chromosome 1p loss J Neurosurg 92 2000 983 990
23. C. Houillier, X. Wang, and G. Kaloshi IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 2010 1560 1566
24. J. Wiencke, S. Zheng, and N. Jelluma Methylation of PTEN promotor defines low-grade gliomas and secondary glioblastoma Neurooncol 9 2007 271 279
25. M. van den Bent, J. Wefel, and D. Schiff Response assessment in neurooncology (a report of the RANO group): Assessments of outcome in trials of diffuse low-grade gliomas Lancet Oncol 12 2011 583 593
26. A. Trotti, A. Colevas, and A. Setser CTCAE v 3.0: Development of a comprehensive grading system for adverse events of cancer treatment Semin Radiat Oncol 13 2003 176 181
27. E. Shaw, R. Arusell, and B. Scheithauer Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/East Cooperative Oncology Group study J Clin Oncol 20 2002 2267 2276
28. J. Grier, and T. Batchelor Low-grade gliomas in adults Oncologist 11 2006 681 693
29. G. Bauman, K. Lote, and D. Larson Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis Int J Radiat Oncol Biol Phys 45 1999 923 929
30. C. Leighton, B. Fisher, and G. Bauman Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation J Clin Oncol 15 1997 1294 1301
31. K. Lote, T. Egeland, and B. Hager Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients J Clin Oncol 15 1997 3129 3140
32. R. Stupp, R. Janzer, and M. Hegi Prognostic factors for low-grade gliomas Semin Oncol 30 suppl 19 2003 23 28
33. T. Daniels, P. Brown, and S. Felten Validation of EORTC prognostic factors for adults with low-grade gliomas: A report using Intergroup 86-72-51 Int J Radiat Oncol Biol Phys 81 2011 218 224
34. S. Yeh, J. Ho, and C. Lui Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas Br J Radiol 78 2005 230 235
35. P. Brown, J. Buckner, and J. O'Fallon Importance of baseline mini-mental status examination as a prognostic factor for patients with low-grade glioma Int J Radiat Oncol Biol Phys 59 2004 117 125
36. E. Chang, A. Clark, and R. Jensen Multi-institutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system J Neurosurg 111 2009 203 210
37. P.R. Schuurman, D. Troost, and B. Verbeeten 5-year-survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: A retrospective analysis of 46 cases Acta Neurochir (Wein) 139 1997 2 7
38. E. Mandonnet, J. Delattre, and M. Tanguy Continuous growth of mean tumor diameter in a subset of grade II gliomas Ann Neurol 53 2003 524 528
39. A. Nicolato, M. Gerosa, and P. Fina Prognostic factors in low-grade supratentorial astrocytomas: A uni-multivariate statistical analysis in 76 surgically treated adult patients Surg Neurol 44 1995 208 221
40. T. Gorlia, W. Wu, and M. Wang New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: A pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials Neurooncol 15 2013 1568 1579
41. M. Hegi, A. Discrens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
42. G. Geiger, W. Fu, and G. Kao Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system Cancer Res 68 2008 3396 3404